Login
$OVID
$2.44 +$0.04 (1.6%) After hours

$OVID SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 S-3
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

NEW YORK, November 10, 2026 – Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including...

24 Aug 2026 144
14 Aug 2026 144
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 10-Q
13 Aug 2026 8-K: Financial Statements and Exhibits

NEW YORK, August 13, 2026 – Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including f...

29 Jul 2026 SCHEDULE 13G
08 Jul 2026 Form 4: Carter Charles Ross, Chief Financial Officer

Received 50,000 shares as a grant or award

08 Jul 2026 Form 3: Carter Charles Ross, Chief Financial Officer

Holds 44,375 shares of Common Stock

08 Jul 2026 SCHEDULE 13G/A
08 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

On July 5, 2026, Ovid Therapeutics Inc. (the “Company”) and Jeffrey Rona, who served as the Company’s Chief Business and Financial Officer, principal financial officer, principal accounting officer and secretary, mutually agreed to Mr. R...

17 Jun 2026 Form 4: Greka Anna, Director

Granted 130,000 Stock Option (right to buy)

17 Jun 2026 Form 3: Greka Anna, Director

No securities owned

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support